Tablet and web-based audiometry to screen for hearing loss in adults with cystic fibrosis
- PMID: 32409613
- DOI: 10.1136/thoraxjnl-2019-214177
Tablet and web-based audiometry to screen for hearing loss in adults with cystic fibrosis
Abstract
Introduction: Individuals with chronic lung disease (eg, cystic fibrosis (CF)) often receive antimicrobial therapy including aminoglycosides resulting in ototoxicity. Extended high-frequency audiometry has increased sensitivity for ototoxicity detection, but diagnostic audiometry in a sound-booth is costly, time-consuming and requires a trained audiologist. This cross-sectional study analysed tablet-based audiometry (Shoebox MD) performed by non-audiologists in an outpatient setting, alongside home web-based audiometry (3D Tune-In) to screen for hearing loss in adults with CF.
Methods: Hearing was analysed in 126 CF adults using validated questionnaires, a web self-hearing test (0.5 to 4 kHz), tablet (0.25 to 12 kHz) and sound-booth audiometry (0.25 to 12 kHz). A threshold of ≥25 dB hearing loss at ≥1 audiometric frequency was considered abnormal. Demographics and mitochondrial DNA sequencing were used to analyse risk factors, and accuracy and usability of hearing tests determined.
Results: Prevalence of hearing loss within any frequency band tested was 48%. Multivariate analysis showed age (OR 1.127; (95% CI: 1.07 to 1.18; p value<0.0001) per year older) and total intravenous antibiotic days over 10 years (OR 1.006; (95% CI: 1.002 to 1.010; p value=0.004) per further intravenous day) were significantly associated with increased risk of hearing loss. Tablet audiometry had good usability, was 93% sensitive, 88% specific with 94% negative predictive value to screen for hearing loss compared with web self-test audiometry and questionnaires which had poor sensitivity (17% and 13%, respectively). Intraclass correlation (ICC) of tablet versus sound-booth audiometry showed high correlation (ICC >0.9) at all frequencies ≥4 kHz.
Conclusions: Adults with CF have a high prevalence of drug-related hearing loss and tablet-based audiometry can be a practical, accurate screening tool within integrated ototoxicity monitoring programmes for early detection.
Keywords: cystic fibrosis; respiratory Infection; systemic disease and lungs.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: AS has received grant funding from Vertex Pharmaceuticals and Gilead Sciences and received personal fees for lecturing from Gilead Sciences. NJS has received personal fees for consultancy and lecturing from Vertex, Teva and Zambon Pharmaceuticals, Chiesi Ltd, Novartis International, Pulmocide Ltd, Roche and Gilead Sciences. CE has received personal fees for consultancy and lecturing from Gilead Sciences, Teva and Zambon Pharmaceuticals.
Similar articles
-
Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides.J Manag Care Spec Pharm. 2021 Feb;27(2):157-165. doi: 10.18553/jmcp.2021.27.2.157. J Manag Care Spec Pharm. 2021. PMID: 33506732 Free PMC article.
-
Globally applicable solution to hearing loss screening: a diagnostic accuracy study of tablet-based audiometry.BMJ Open. 2025 May 22;15(5):e097550. doi: 10.1136/bmjopen-2024-097550. BMJ Open. 2025. PMID: 40404318 Free PMC article. Clinical Trial.
-
Extended High-Frequency Audiometry Using the Wireless Automated Hearing Test System Compared to Manual Audiometry in Children and Adolescents.Ear Hear. 2025 May-Jun 01;46(3):782-795. doi: 10.1097/AUD.0000000000001621. Epub 2024 Dec 26. Ear Hear. 2025. PMID: 39722183
-
Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.Ear Hear. 2018 Jan/Feb;39(1):69-84. doi: 10.1097/AUD.0000000000000464. Ear Hear. 2018. PMID: 28708814 Free PMC article.
-
Using tablet-based technology to deliver time-efficient ototoxicity monitoring.Int J Audiol. 2018 Sep;57(sup4):S25-S33. doi: 10.1080/14992027.2017.1370138. Epub 2017 Sep 12. Int J Audiol. 2018. PMID: 28893111 Review.
Cited by
-
Clinical Observations in Patients With Cystic Fibrosis-Related Diabetes and Self-Reported Ototoxicity Symptoms.Am J Audiol. 2023 Nov 28;33(1):1-9. doi: 10.1044/2023_AJA-22-00237. Online ahead of print. Am J Audiol. 2023. PMID: 38016170 Free PMC article.
-
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.Am J Audiol. 2021 Oct 11;30(3S):800-809. doi: 10.1044/2021_AJA-21-00031. Epub 2021 Sep 22. Am J Audiol. 2021. PMID: 34549989 Free PMC article.
-
Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.J Cancer Surviv. 2024 Apr 17. doi: 10.1007/s11764-024-01586-3. Online ahead of print. J Cancer Surviv. 2024. PMID: 38630333
-
Digital Approaches to Automated and Machine Learning Assessments of Hearing: Scoping Review.J Med Internet Res. 2022 Feb 2;24(2):e32581. doi: 10.2196/32581. J Med Internet Res. 2022. PMID: 34919056 Free PMC article.
-
Cost-effectiveness of implementing routine hearing screening using a tablet audiometer for pediatric cystic fibrosis patients receiving high-dose IV aminoglycosides.J Manag Care Spec Pharm. 2021 Feb;27(2):157-165. doi: 10.18553/jmcp.2021.27.2.157. J Manag Care Spec Pharm. 2021. PMID: 33506732 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous